Smith, a microbiologist whose discovery revolutionize the field of genetic engineering, was a Johns Hopkins School of Medicine alumnus and professor emeritus ...

Vancouver, Canada, November 4th, 2025, FinanceWire Equity Insider News Commentary – The precision medicine sector reached ...

T cell therapies have revolutionized cancer treatment—but so far, their success has been largely limited to blood cancers. Solid tumors, which account for around 90% of all adult cancers, remain a ...

Recognized in the Biotechnology category of the 2025 Top Innovations contest, small Cas12l nucleases are versatile, ...

Azalea's first drug candidate is a CAR-T therapy for cancer and autoimmune conditions that turns immune cells into cancer ...

A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed ...

It is a smart strategy to diversify your portfolio by investing in high-quality companies built on proven technologies.

Pairwise has licensed its Fulcrum® gene editing platform to the International Rice Research Institute (IRRI), a non-profit agricultural research organization. The agreement will enable IRRI to apply ...

BERKELEY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced management will ...

Understanding how cells turn genes on and off is one of biology's most enduring mysteries. Now, a new technology developed by chemist Brian Liau and his collaborators at Harvard offers an ...

Caribou Biosciences shares rose after its CAR-T therapies showed high response rates and durable remissions in lymphoma and myeloma trials.

Innovation is never easy. It requires the audacity to create a new path, one where we will encounter novel obstacles that demand both resourcefulness and bold imagination. But when we stand together, ...